Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.

The pharmacogenomics journal - 1 Jun 2014

Sebio A, Páez D, Salazar J, Berenguer-Llergo A, Paré-Brunet L, Lasa A, Del Río E, Tobeña M, Martín-Richard M, Baiget M, Barnadas A

Abstract excerpt

In the epidermal growth factor receptor (EGFR) pathway, polymorphisms in EGFR and its ligand EGF have been studied as biomarkers for anti-EGFR treatment. However, the potential pharmacogenetic role of other EGFR ligands such as amphiregulin (AREG) and epiregulin (EREG) has not been elucidated. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Camptothecin
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Primers

Share to ErbB Receptors

Share to Irinotecan

Share to Neoplasm Metastasis

Share to Real-Time Polymerase Chain Reaction

Source

Identifiers

PMID: 23959273
DOI: 10.1038/tpj.2013.29

Genes

EGFR
AREG
EGF
EREG
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23959273-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan.PMID 23959273Read ↗

Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.Semantic proximity Read ↗

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).Semantic proximity Read ↗

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.Semantic proximity Read ↗

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

Epigenetic regulation of Amphiregulin and Epiregulin in colorectal cancerSemantic proximity Read ↗

[Predictive factors of response to anti-EGFR treatments in colorectal cancer].Semantic proximity Read ↗

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Semantic proximity Read ↗

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.Semantic proximity Read ↗

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.Semantic proximity Read ↗

Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer.Semantic proximity Read ↗

Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.